Skip to Main Content

Program Members

Clinical Program Leader

Disease Aligned Research Team Leader


Medical Oncology


  • Professor of Surgery (Oncology); Chief Medical Officer, Yale Cancer Center; Professor, Surgery

    As Chief Medical Officer, Dr. Billingsley is responsible for clinical cancer care across Yale Cancer Center, Smilow Cancer Hospital, and the Smilow Cancer Hospital Care Centers, as well as clinical program development for cancer services throughout Yale New Haven Health. Among his many responsibilities, he oversees quality and patient safety initiatives, evaluates and optimizes our multidisciplinary team structure, assists  with facilities and space planning, supports our research mission, and interacts and coordinates with Yale New Haven Hospital's clinical leadership structure. Learn more about Dr. Billingsley >>Dr. Billingsley is an international leader in the clinical care and research of hepatobiliary cancers, and maintains a surgical practice for the care of patients with liver cancer, cholangiocarcinoma, gallbladder cancer, and pancreatic cancer.  During the course of his career, Dr. Billingsley has developed a particular focus on the treatment of patients with metastatic tumors to the liver.   His approach involves extensive multidisciplinary coordination with medical oncologists, interventional radiologists, and other specialists.  Dr. Billingsley employs a range of technical approaches in treating patients with liver and pancreatic tumors, including the use of minimally invasive techniques whenever possible.   In his own practice, and in his leadership of clinical care across the Smilow Care Network, Dr. Billingsley believes that highest quality clinical care rests on a foundation of scientific and technical excellence, delivered with compassion and respect for each individual patient and their family. Dr. Billingsley explains, "It is an honor for me to work with and lead a truly outstanding group of cancer care professionals at Yale Cancer Center and the Smilow Network. It is a privilege for us to serve our patients."Learn more about Dr. Billingsley>>
  • Associate Professor of Surgery (Oncology); Section Chief, Hepato-Pancreato-Biliary (HPB) and Mixed Tumors; Co-Director of Team Science, Yale Center for Clinical Investigation (YCCI)

    Sajid Khan, MD is an Associate Professor of Surgery and Section Chief of Hepato-Pancreato-Biliary and Mixed Tumors at Yale School of Medicine, and Co-Director of Team Science at Yale Center for Clinical Investigation. He earned his medical degree from State University of New York Health Science Center at Syracuse and is Board Certified in both Complex General Surgical Oncology and General Surgery. He completed general surgery training at Oregon Health and Science University in Portland, OR and Albert Einstein College of Medicine/Montefiore in the Bronx, NY. He also completed a research fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center in New York, NY and a clinical and research fellowship in surgical oncology at The University of Chicago Medical Center in Chicago, IL. Watch a video with Dr. Sajid Khan >>Dr. Khan is dedicated to improving the lives of patients with cancer through his clinical practice and research endeavors. His clinical practice specializes in the surgical management of patients with benign and malignant tumors of the liver, pancreas, bile ducts, gallbladder, stomach, and colon. Additionally he treats individuals diagnosed with cutaneous malignancies and soft tissue sarcomas, neuroendocrine tumors, and cystic diseases of the pancreas. His commitment to the care of his patients incorporates a multidisciplinary team approach in addition to state of the art minimally invasive surgical techniques. He is an active member of the National Comprehensive Cancer Center (NCCN), Society of Surgery of the Alimentary Tract (SSAT), Society of Surgical Oncology (SSO),  Society of University Surgeons (SUS), Association for Academic Surgery (AAS), Southwest Oncology Group (SWOG), American College of Surgeons (ACS), American Society of Clinical Oncology (ASCO), Yale Center for Clinical Investigation (YCCI), Yale Cancer Center, and Yale School of Medicine Admissions Committee. In addition to his clinical practice, Dr. Khan is also involved in clinical translational research studying cancer metastases and differences in tumor biology based on ethnicity/race and sex.  Dr. Khan is an NIH-funded, well published, surgeon-scientist who seeks to use modern molecular biology to improve our understanding and treatment of patients with gastrointestinal cancers. Using molecular and clinical markers, he identifies patients with a limited number of metastases (oligometastasis) who will benefit from curative surgical resections. In addition, his lab studies the relationship with metabolite and protein expression on colon cancer patient outcomes based on race/ethnicity and sex. He also performs clinical outcomes research in all types of gastrointestinal cancers. Dr. Khan has been recognized for excellence in both clinical care and research in oncology.
  • Lampman Professor of Surgery (Oncology); Section Chief, Surgical Oncology

    Ronald R. Salem, MD earned his medical degree from University of Rhodesia and is a Board Certified Surgeon. Passionate about improving the lives of patients with cancer, he is committed to advancing medical and surgical treatment and integrating the latest techniques and minimally invasive surgery in his clinical practice. He is one of the few surgeons in Connecticut with a high volume practice performing the Whipple procedure. Dr. Salem specializes in malignant and pre-malignant diseases of the pancreas, liver and biliary system, the gall bladder, stomach, colon and rectum, lymphoma, neuroendocrine tumors of the pancreas and gastrointestinal tract, as well as liver tumors in pregnant women. His clinical research includes a special focus on optimizing clinical outcomes in patients undergoing pancreatic surgery, combined modality therapy for esophageal cancer and the management of pancreatic cysts and benign and malignant liver tumors. He has received many honors and recognitions, including The Best Doctors, N.Y. Metro Area annually for over ten years; Best Doctors in Connecticut and Top Minimally Invasive Surgeons, NY Metro Area. He was recently awarded the prestigious David and Cindy Lefell Award for clinical excellence, the Yale New Haven Hospital Heroes Award, the Smilow Cancer Center Clinical Award the Alvin Feinstein Teaching Award and has received the Chief Resident in Surgery Teaching Award on seven separate occasions.


  • Professor of Surgery (Transplant); Division Chair, Transplantation Surgery and Immunology, Surgery

    David C. Mulligan, MD, is an abdominal organ transplant surgeon performing both living and deceased donor liver, kidney, and pancreas transplants. He currently serves as Professor and Chair of Transplantation and Immunology in the Department of Surgery at Yale School of Medicine/Yale New Haven Health System.His clinical and academic focus surrounds living donor liver transplantation, expanding donation, and working on ways to utilize ex-vivo organ perfusion systems to increase transplantation in the United States.Dr. Mulligan and his team are testing novel strategies in immunosuppression; improved biomechanical organ preservation methods to reduce ischemia/reperfusion injury and promote regeneration; and working in the field of 3D bioprinting to collaborate in finding ways to grow new organs from stem cell precursors.He has performed more than 250 living donor transplants and has authored more that 180 publications. He also has served on numerous editorial review boards and presented across the U.S. and internationally.Dr. Mulligan’s leadership in solid organ transplantation across national and international platforms has grown considerably and he now serves as Immediate Past President of the United Network of Organ Sharing (UNOS)/Organ Procurement Transplant Network (OPTN), Member at-large on the Governing Board of the American Association for the Study of Liver Diseases, Past Chair of the Advisory Council on Transplantation (ACOT) to the Secretary of HHS, special government employee for FDA Medical Device Advisory Committee and chair of the Business Practice Committee of the American Society of Transplant Surgeons. He also contributes to the oversight and recommendations regarding the impacts of COVID-19 on solid organ transplantation in the U.S. for both the AASLD and the ASTS.In these visionary roles, he has led major changes in organ allocation and distribution and will hopefully culminate in substantial increases in organ transplants. Passionate about patient-centered care and building more resilient teams, he makes time to share his enjoyment of spending time in nature, especially near the ocean, with his wife and three children.


  • Professor of Pathology and of Medicine (Digestive Diseases)

    Dr. Dhanpat Jain is a Professor of Pathology and Internal Medicine (section of Digestive Diseases). Dr. Jain graduated from Mysore Medical College, Mysore, India and received his M.B.B.S degree in 1986. He subsequently received his M.D. Pathology degree from Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India in 1991. He moved to the U.S. in 1995 and completed his Anatomic Pathology residency and Fellowship in Gastrointestinal Pathology at Yale University School of Medicine, and subsequently continued as a faculty there.Dr. Jain is a nationally and internationally recognized gastrointestinal pathologist known for his diagnostic skills, research and teaching. He has more than 150 publications, many book chapters, books and reviews, all of which are largely in the field of gastrointestinal and liver pathology. He has delivered many lectures and participated in many courses at the national and international level. He is on the editorial board of several high impact journals in the field of gastrointestinal and liver disorders. His area of expertise is motility disorders of the gastrointestinal tract, for which he gets cases in consultation from across the globe. Dr. Jain is an accomplished teacher and has received many awards. He has continuously been nominated for “Best Doctors in America” for many years.
  • Anthony N. Brady Professor of Pathology; Chair, Pathology; Chief of Pathology, YNHH, Pathology

    Dr. Liu is an expert in viral hepatitis, liver cancer immunotherapy, graft-versus-host disease, and cancer epigenetics. Dr. Liu is Chair of the Department of Pathology and Chief of Pathology at Yale New Haven Hospital. After obtaining his medical degree at Tong Liao Medical College at Inner Mongolia University of Nationality and completing his postgraduate training at Peking Union Medical College in China, Liu received his PhD in pathology from the University of Pennsylvania School of Medicine. He completed his residency in anatomical and clinical pathology at Medical College of Pennsylvania, held an oncological pathology fellowship at M.D. Anderson Cancer Hospital, and had postdoctoral training at Scripps Clinic. Before his appointments at Rutgers in 2015, he was professor and vice chair of pathology, immunology, and laboratory medicine at the University of Florida, where he also held an endowed chair in gastrointestinal and liver research.
  • Professor of Pathology and of Medicine (Digestive Diseases); Director, Program in Gastrointestinal and Liver Pathology, Pathology

    Dr. Robert is a gastrointestinal, liver and pancreaticobiliary surgical pathologist. She completed her undergraduate and medical school education at the University of Michigan, followed by residency training in Anatomic and Clinical Pathology and a fellowship in gastrointestinal pathology at the University of California, Los Angeles. She was an assistant professor at the University of California, San Francisco, specializing in liver transplant pathology prior to joining the Department of Pathology at Yale University School of Medicine in 1994. Dr. Robert served as the Director of the Program in Gastrointestinal Pathology and the Director of the Fellowship in Gastrointestinal Pathology for over ten years. In addition to extensive clinical activities, Dr. Robert participates in clinical and translational research, and collaborates with scientists in the basic sciences at Yale School of Medicine. Her research interests include liver transplantation, inflammatory bowel diseases, celiac disease, stromal responses in pancreatic cancer and colitis induced by immune therapies, such as immune checkpoint inhibitors.
  • Associate Professor of Pathology; Associate Director, Gastrointestinal & Liver Pathology; Director, Gastrointestinal & Liver Pathology Fellowship Program

    Xuchen Zhang, MD, PhD, is an Associate Professor of Pathology who is board-certified in both anatomic and clinical pathology. He has clinical interests and expertise in liver/gastrointestinal pathology, liver neoplasms, liver transplant pathology, and neoplastic and non-neoplastic pulmonary pathology. His research interests are acute and chronic oxidant-induced lung injury, liver neoplasms, alcoholic and non-alcoholic liver diseases, colorectal cancer and underlying molecular mechanisms.

Radiation Oncology

  • Assistant Professor of Therapeutic Radiology

    Sanjay Aneja, MD is an Assistant Professor within the Department of Therapeutic Radiology at Yale School of Medicine. Dr. Aneja is a physician scientist whose research group is focused on the application of machine learning techniques on clinical oncology. He received his medical degree from Yale School of Medicine and served as class president. During medical school he completed a research fellowship at the Department of Health and Human Services in large scale data analysis. He later completed his medicine internship at Memorial Sloan Kettering Cancer Center followed by his residency in radiation oncology at Yale-New Haven Hospital. During his residency he completed his post-doc in machine learning at the Center for Outcomes Research and Evaluation (CORE) receiving research grant from IBM Computing. He is currently a recipient of an NIH Career Development award, an NSF research grant, and an American Cancer Society research award.The Aneja Labs on-going efforts include: 1) Deep Learning to Derive Imaging Based Biomarkers of Cancer Outcomes: We have previously shown the ability for deep learning to derive imaging-based biomarkers for lung cancer and are currently applying our deep learning platform to brain metastases. We have developed a national consortium of 7 institutions whom have contributed data to our effort. This project is funded by the NIH, AHRQ, Radiation Society of North America (RSNA), and the American Cancer Society.2) AI-Driven Collection of Patient Reported Outcomes: Our group is developing deep learning algorithms which use patient audio diaries to predict validated patient reported outcome metrics. Through a collaboration with Amazon, we hope to integrate our algorithm into virtual assistants and pilot them in a clinical setting. 3) Machine Learning Methods for Clinical Trial Classification: Our group, through a collaboration with SWOG and an industry partner, is studying the ability of machine learning to classify cancer clinical trials and match clinicians to relevant randomized clinical trials. This project is currently funded by the NSF and SWOG Hope Grant.


  • Associate Professor of Clinical Radiology and Biomedical Imaging; Radiology Director for Male Interventional Health

    I am a board-certified Interventional Radiologist, which means I perform image-guided minimally invasive surgical procedures. These procedures are done by passing a specialized needle or catheter into a small hole in the skin, and from there I use radiographic, ultrasound, or CT-scan guidance to steer my instruments through blood vessels or soft tissues into the organ that I wish to treat. Almost every procedure can be done with IV sedation medication alone, so the patient does not need general anesthesia. Most patients usually can return home the same day with only a small bandage on, and they can often can go back to their normal activities after only a day or two of recovery at home. Watch a video with Dr. Raj Ayyagari>>I perform procedures in every part of the body, but I specialize in some remarkable minimally invasive procedures that are available to treat problems that patients have in their urinary and reproductive organ systems, problems that can severely impact quality of life or even life expectancy. These procedures can treat such problems successfully and safely, while allowing patients to avoid more invasive surgery.Prostatic artery embolization (PAE) is a remarkable procedure that is a safe and highly effective yet minimally invasive outpatient procedure that shrinks the prostate dramatically. This helps older men with benign prostatic hyperplasia (BPH) regain the ability to urinate normally again, without having to go through more invasive surgeries like a TURP (Trans-Urethral Resection of Prostate) or prostatectomy. This is truly a revolutionary procedure that has helped many men regain control of their lives, after suffering from what can become a severe medical condition that controls one's life.For patients with concerns for prostate cancer, we are one of the few centers in the country that perform MRI-guided prostate biopsies through the skin (the "perineum") instead of going through the rectum (as is done with standard prostate biopsies). This technique allows us to directly target specific areas of concern in the prostate under direct imaging guidance, while avoiding much of the infection risk that comes with performing prostate biopsies via the rectum.We are now one of a handful of centers in the country that perform a procedure called MRI-guided prostate cancer ablation. This is a minimally invasive technique performed via the urethra that allows us to treat prostate cancer without creating any incisions, often permitting the patient to return home the same day. The procedure is an excellent option for patients who are not necessarily good surgical candidates, and can be performed in selected patients after a thorough evaluation and conversation with both the a urologist specializing in cancer treatment and the Interventional Radiology team.For both younger and older male patients with large dilated veins in their scrotum, a common problem known as a varicocele, I also perform a safe and highly effective and minimally invasive outpatient procedure called embolization that closes these veins and shrinks them down. This procedure is a way to treat the pain, cosmetic problems, or even concerns for fertility (ability to have children) that can plague patients with this condition.
  • Assistant Professor; Resident in Radiology and Biomedical Imaging

    Dr. Chapiro joined the Department of Radiology and Biomedical Imaging as a research scientist and interventional radiology resident from Berlin, Germany. After graduating from the University of Leipzig and upon completion of his research thesis at the Justus-Liebig University in Giessen with summa cum laude, he served as a postdoctoral research fellow in interventional oncology at The Johns Hopkins Hospital and then as radiology resident at the Department of Radiology, Charité University Hospital in Berlin.Dr. Chapiro’s research focuses on developing new quantitative imaging biomarkers for the diagnosis, characterization, and therapeutic management of liver cancer. His translational research portfolio includes the development of novel embolic agents as well as the application of artificial intelligence solutions for the management of liver cancer. His basic research interest mainly focuses on developing new tools to characterize the tumor microenvironment and the immune system in the setting of loco-regional, image-guided therapies of liver cancer.Creating innovative and clinically applicable imaging solutions for liver cancer with advanced molecular imaging, image post-processing and machine learning approaches and translating them to clinical practice has been his central mission for the past decade. He authored and co-authored >100 original research articles, reviews and book chapters and gave more than 70 talks and invited lectures within the last five years. His research has also resulted in several patents, 510(k)-approved medical products and significant grant support from federal, foundational and industry sources. He is an active research mentor to more than 30 undergraduate, medical and graduate students as well as peers both at Yale and other national and international institutions. Being an active contributor, journal-, abstract- and grant reviewer in several professional societies (RSNA, SIR and SIO), he is also committed to education and the mission of disseminating research data and scientific knowledge. Dr. Chapiro consults the Editorial Board of the Journal of Hepatology, is a member of the American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) Steering Committee, he additionally serves on the Society of Interventional Oncology Research Committee and is the incoming Chair of the Annual Meeting Program Planning Committee for the Subspecialty of Interventional Radiology at the Annual Radiological Society of North America meeting 2021-2023. He is the co-initiator of the "Rising Star" Student Exchange Program in collaboration with the Charité University Hospital in Berlin and co-directs the Yale Interventional Oncology Research Laboratory. Dr. Chapiro is the Associate Director of the Clinical and Translational Core of the Yale Liver Center.
  • Professor of Radiology and Biomedical Imaging; Chief, Body Imaging Section; Chief, Body Computed Tomography (CT)

    Gary Israel, MD, Professor and Section Chief of Abdominal Section.  Dr. Israel earned his medical degree at New York Medical College, and completed a residency and fellowship in diagnostic radiology at Montefore Medical Center and New York University Medical Center, respectively. Dr. Israel’s expertise is abdominal imaging with a particular focus on genitourinary imaging (GU), using both CT and MRI. He has particular interest in the CT and MR evaluation of renal masses and CT and MR. He also has expertise in GI radiology including CT colonography.
  • Professor of Radiology & Biomedical Imaging and Medical Oncology; Vice Chair for Clinical Research, Radiology & Biomedical Imaging; Section Chief, Interventional Radiology

    Dr. David C. Madoff is Professor of Radiology & Biomedical Imaging and Medical Oncology at Yale School of Medicine. His current administrative roles are Vice Chair for Clinical Research and Section Chief of Interventional Radiology. Dr. Madoff earned his B.A. from Emory University and his M.D. from the University of Pittsburgh. He completed both his internship in Internal Medicine and residency in Radiology at SUNY at Stony Brook and his fellowship training in Vascular and Interventional Radiology at The University of Texas MD Anderson Cancer Center. Dr. Madoff achieved Board Certification in Diagnostic Radiology from the American Board of Radiology in 2000 and attained his Certificate of Added Qualifications in Vascular and Interventional Radiology in 2002. He was a faculty member in the Section of Interventional Radiology at MD Anderson Cancer Center in Houston, Texas for a decade before joining New York-Presbyterian Hospital/Weill Cornell Medical Center in 2011. While at Weill Cornell, Dr. Madoff served as Division Chief of Interventional Radiology from 2011 to 2015 and Vice Chair for Academic Affairs from 2015 to 2019. He moved to Yale in July, 2019.Dr. Madoff has a strong background in clinical care and has treated many patients with complex oncological problems. His clinical interests are wide-ranging, and have included visceral vascular, hepatobiliary and genitourinary interventions, various embolotherapy and percutaneous biopsy techniques and many specialized therapies within the realm of Interventional Oncology. In particular, Dr. Madoff is world-renowned for his work on preoperative portal vein embolization, a technique used to improve the safety of major hepatic resection. This technique is based on the liver's ability to regenerate and has been used in patients with primary and metastatic hepatobiliary cancer to increase the size of the anticipated liver remnant before surgery. Without this procedure, many patients with potentially resectable disease would not be eligible for curative resection.Dr. Madoff is a leader in academic Interventional Radiology and has been an invited speaker at numerous national and international meetings. He authored or co-authored over 160 peer-reviewed scientific articles, has written more than 30 book chapters and served as co-editor of four textbooks including Venous Embolization of the Liver: Radiologic and Surgical Practice (2011), Clinical Interventional Oncology (2014) and Interventional Radiology: Fundamentals of Clinical Practice (2019). Dr. Madoff served as Deputy Editor-in-Chief for the Journal of Vascular and Interventional Radiology from 2007 to 2010 and Deputy Editor for Radiology from 2012 to 2017. Dr. Madoff currently serves as founding co-Editor-in-Chief for Digestive Disease Interventions and on the editorial boards of additional publications that include Techniques in Vascular and Interventional Radiology, Seminars in Interventional Radiology, European Radiology Experimental, Cancer Biology & Medicine, Chinese Clinical Oncology and Current Oncology Reports. Dr. Madoff is active in many of the major radiological societies including the Radiological Society of North America, the American Roentgen Ray Society, the Society of Interventional Radiology and the Association of University Radiologists and serves on the Board of Trustees of the American Registry of Radiologic Technologists (ARRT). Based on his important contributions to the field, Dr. Madoff was elected Fellow of the Society of Interventional Radiology in 2007, the American College of Radiology in 2015 and the Cardiovascular and Interventional Radiology Society of Europe in 2018.
  • Robert I. White, Jr. Professor of Radiology and Biomedical Imaging; Director, Yale Hereditary Hemorrhagic Telangiectasia Program; Director, Vascular and Interventional Radiology Fellowship Program

    Dr. Pollak went to medical school at the Columbia University College of Physicians & Surgeons and subsequently did his Diagnostic Radiology residency at the Columbia-Presbyterian Medical Center. His fellowship in Vascular & Interventional Radiology was at the Hospital of the University of Pennsylvania. He then joined the Yale University School of Medicine Department of Radiology and Biomedical Imaging in the section of V&IR and served as the section chief and director of the fellowship program in this sub-specialty for over two decades. While active in all aspects of vascular & interventional radiology, his current major interests are embolotherapy (embolization), including for acquired and congenital vascular abnormalities and malformations (other than in the brain), fibroids, and malignancies, as well as other minimally invasive treatments for tumors, including local ablation. In addition, he is an expert in vascular procedures in the liver, such as intrahepatic portosystemic shunts and venous procedures, such as inferior vena cava filters. Dr. Pollak is the current director of the multidisciplinary Yale Hereditary Hemorrhagic Telangiectasia Program, which was started as the first of its kind in the world in the early 1990s. As such, he has extensive experience in the evaluation and management of patients with this genetic disorder, with particular expertise in embolization of pulmonary arteriovenous malformations, which frequently occur in this population. Dr. Pollak is also the co-director of the Yale Pulmonary Embolism Response Team, a multidisciplinary group of physicians interested in the advancement of the management of patients with this condition, especially those with more severe manifestations.
  • Professor of Radiology and Biomedical Imaging; Director, MRI Services; Chief, MRI Service

    Dr. Jeffrey C. Weinreb is Director of the MRI Service at Yale-New Haven Hospital and Professor in the Department of Radiology and Biomedical Imaging at the Yale School of Medicine.  After graduating Phi Beta Kappa from the MIT, he received his MD from the Icahn School of Medicine at Mount Sinai.  He has held faculty positions at UT Southwestern Medical School, Columbia College for Physicians and Surgeons, and NYU School of Medicine, where he was Director of MRI for 15 years and led a group that pioneered the development of Body MRI.  For more than three decades, Dr. Weinreb has been an innovator in MRI. He is a leading authority on MRI contrast agents and MRI safety, and he has made seminal contributions to clinical applications of MRI in the abdomen, spine, breast, prostate, breast, vascular system, obstetrics, and gynecology. He has authored/co-authored three textbooks and more than 230 peer reviewed manuscripts, served on the editorial boards of numerous medical journals, and presented more than 1000 invited lectures throughout the world. Dr. Weinreb was the Principal Investigator for the NCI sponsored cooperative Multicenter Study of In Vivo MR Spectroscopy for the Evaluation of Prostate Cancer, and led an international effort to develop PI-RADS (Prostate Imaging Reporting and Data System) to standardize the acquisition, interpretation, and reporting of prostate MRI. In 2018 he was one of the organizers for the NIH/NIBIB workshop on clinical manifestations of gadolinium deposition. He recently helped to develop joint ACR-National Kidney Foundation consensus recommendations for the use of intravenous contrast media in patients with renal disease.  Dr. Weinreb has had numerous leadership position in professional organizations, including Vice President of the American College of Radiology, Chairman of the ACR Forum, member of the ACR Board of Chancellors, President of the New York Roentgen Society, and President of the SCBT-MR. As Chairman of the ACR Commission on Quality and Safety and Chairman of the ACR MRI Accreditation Program, Dr. Weinreb spearheaded efforts to improve the quality of medical imaging in the United States. He has received numerous awards, including the Gold Medal Awards in 2017 from the ACR and the in 2019 from the SCBT-MR (now called the SABI).

Patient Care